U.S. Pharma Stock News

In early January 2026, Mobileye announced that a major U.S.-based automaker will use its EyeQ6H chip to power Surround ADAS hands-free driving systems as standard on millions of mainstream and premium vehicles worldwide. The deal lifts Mobileye’s estimated future EyeQ6H Surround ADAS deliveries to more than 19 million units, underlining how software-defined, single-chip architectures are increasingly central to automakers’ next-generation safety and automation plans. We’ll now examine how...

Photronics (PLAB) recently drew investor attention after its shares rose 5.4% in afternoon trading, following more optimistic earnings expectations and supportive news across the semiconductor sector, including stronger revenue guidance from peer Microchip Technology. See our latest analysis for Photronics. Those upbeat earnings expectations sit against a share price of $34.86 and a strong recent run, with a 30-day share price return of 38.06% and a 1-year total shareholder return of 43.93%...

If you are wondering whether Ascendis Pharma's current share price fairly reflects its prospects, you are not alone. Many investors are asking the same question right now. The stock recently closed at US$213.28, with returns of 0.0% over 7 days, 3.0% over 30 days, 0.0% year to date and 58.7% over 1 year, while the 3 year and 5 year returns stand at 87.7% and 28.9% respectively. Recent coverage has focused on Ascendis Pharma's progress and market position in pharmaceuticals and biotech. This...

If you are wondering whether Indivior at around US$35.89 still offers value after a strong run, this article will walk through what the current price might be implying about the company. The stock has delivered a 196.9% return over the last year and a 414.6% return over five years, although the last 30 days saw a 1.9% decline and the last week was flat. Investors have been reacting to ongoing news flow around the company and its position in the pharmaceutical and biotech space, which...

If you are wondering whether KLA's share price still reflects fair value after a strong run, this breakdown will help you see what the current market price might be pricing in. With the stock at US$1,359.69 and reported returns of 11.9% over 7 days, 11.0% over 30 days, 6.7% year to date, 99.8% over 1 year, 234.1% over 3 years and 394.6% over 5 years, many investors are asking what kind of valuation justifies those numbers. Recent coverage has focused on KLA's position in semiconductor...

If you are wondering whether Stanley Black & Decker is offering fair value at around US$78.69, you are not alone. This article is here to break that question into clear, practical pieces. The stock has returned 5.9% over the last 7 days, 8.7% over the last 30 days, 2.9% year to date and 1.0% over the last year, while the 3 year return is 3.2% and the 5 year return reflects a 46.5% decline. Recent coverage has focused on how investors are reassessing long term expectations for tool and...

If you are wondering whether Walt Disney's current share price is a fair deal or not, this article will walk through what the numbers are actually saying about the stock. The shares last closed at US$112.91, with returns of 4.9% over 30 days, 0.9% year to date and 4.0% over 1 year, while the 3 year return is 20.0% and the 5 year return is a 34.4% decline. Recent headlines around Disney have focused on its ongoing efforts to reshape its media and entertainment businesses, including content...

If you are wondering whether Incyte shares still offer value at current levels, you are not alone. This article is designed to walk you through that question step by step. Incyte's share price closed at US$110.57 recently, with total returns of 11.9% over 7 days, 14.3% over 30 days, 9.0% year to date, 51.2% over 1 year, 38.8% over 3 years and 19.2% over 5 years. This naturally raises questions about what is already priced in. Recent news around Incyte has focused on its position in the...

In recent days, Galaxy Digital has seen a jump in trading activity as investors refocused on crypto-related firms amid a recovering Bitcoin market. This renewed attention underscores how closely Galaxy’s diversified digital-asset operations are tied to shifts in broader crypto sentiment and volatility. We’ll now explore how this renewed trading interest, tied to Bitcoin’s recovery, might influence Galaxy Digital’s existing investment narrative. Trump's oil boom is here - pipelines are...

Recent trading in MSC Industrial Direct (MSM) has drawn attention after a one-month return of about a 1% decline and a three-month return of roughly an 8% decline, prompting closer scrutiny of its fundamentals. See our latest analysis for MSC Industrial Direct. Those near term share price declines sit against a softer year to date share price return of 5.6% and a 1 year total shareholder return of 2.3%. This suggests momentum has been fading rather than picking up despite the current US$81.08...

Red Rock Resorts (RRR) has drawn fresh attention after recent share moves, with the stock returning about 9% over the past month and 6.6% in the past 3 months, despite a negative year to date performance. See our latest analysis for Red Rock Resorts. That recent 9% 1 month share price return sits alongside a small year to date share price decline and a much stronger 45.16% 1 year total shareholder return. Together, these figures suggest momentum has cooled in the near term but remains solid...

Altimmune, Inc. recently announced that the FDA has granted Breakthrough Therapy Designation to pemvidutide, its balanced 1:1 glucagon/GLP-1 dual receptor agonist, for treating patients with metabolic dysfunction-associated steatohepatitis (MASH), based on encouraging Phase 2b IMPACT trial data and a completed end-of-phase 2 meeting aligning on a registrational Phase 3 program. The planned Phase 3 trial will not only pursue biopsy-based endpoints for a potential accelerated approval but also...

Full Truck Alliance (NYSE:YMM) is back on investor radar after Hong Kong based Bright Valley Capital built a new US$33.36 million position, and recent revenue data highlights growth in transaction and value added services. See our latest analysis for Full Truck Alliance. Despite Bright Valley Capital’s new stake and solid revenue from transaction and value added services, sentiment around Full Truck Alliance has been mixed, with a 30 day share price return of 8.06% decline and a 90 day share...

Executive share grant and recent pullback put Kinsale in focus Kinsale Capital Group (KNSL) has attracted fresh attention after its share price pullback and a new equity grant of 460 restricted shares to its president and COO, which vests after one year of service. See our latest analysis for Kinsale Capital Group. The recent pullback, including a 16.35% 3 month share price return and a 1 year total shareholder return decline of 5.43%, comes after a strong 3 year total shareholder return of...

Academy Sports and Outdoors (ASO) has recently drawn investor attention after its shares fluctuated between a negative 1-day return and gains over the past week, month, and past 3 months, prompting closer scrutiny of its fundamentals. See our latest analysis for Academy Sports and Outdoors. The recent 7 day share price return of 13.87% and 30 day gain of 16.46% come after a year to date share price return of 9.09%. At the same time, the 1 year total shareholder return shows a 2.31% decline,...

Lumen Technologies, through its Level 3 Financing subsidiary, recently upsized and completed offerings of 8.500% Senior Notes due 2036 to about US$1.25 billion, using proceeds to repurchase existing second lien notes and support general corporate purposes as it continues shifting away from consumer services. These moves, alongside the sale of its remaining consumer fiber network to AT&T and a stronger-than-expected Q3, underline a major reorientation toward enterprise-focused connectivity...

United States Antimony recently promoted Melissa Pagen to President and Chief Operating Officer of its Bear River Zeolite division, following her role in securing a US$245,000,000 Defense Logistics Agency contract and a US$106,700,000 supply agreement. The company is emphasizing Bear River Zeolite as a long-lived asset, highlighting over 400 years of zeolite reserves that management believes can support a larger revenue base under Pagen’s leadership. We’ll now examine how Pagen’s promotion...

Rayonier stock: recent performance snapshot Rayonier (RYN) has attracted fresh attention after recent trading left the shares at US$21.66, with returns near flat over the past week and a negative move over the past 3 months and year. See our latest analysis for Rayonier. At the current share price of US$21.66, Rayonier’s recent drift lower, including a 17.45% 3 month share price decline and a 6.67% 1 year total shareholder return decline, points to fading momentum as investors reassess its...

If you are wondering whether Leonardo DRS is still reasonably priced after its recent run, this article walks through what the current numbers may imply about value. The stock most recently closed at US$37.20, with returns of 9.1% over 7 days, 9.7% over 30 days, 7.0% year to date and 12.9% over the past year, as well as a very large 3 year return of 194.0%. Recent coverage has focused on Leonardo DRS as a US defense and electronics business, with investors watching how its positioning in...

Earlier this month, C3.ai CEO Stephen Bradley Ehikian sold 234,918 shares for about US$3,185,488, as the company continues to wrestle with declining revenue, margin pressure, and cautious guidance under new leadership. This sizable insider sale, coming after a difficult year and with only a limited number of new production and generative-AI contracts signed, is sharpening investor focus on management’s confidence in the business outlook. We’ll now examine how this large CEO share sale might...

Elanco Animal Health recently secured USDA approval for Befrena, a new anti‑IL31 monoclonal antibody injection for canine allergic and atopic dermatitis, dosed every 6 to 8 weeks and expected to launch in the first half of 2026. This marks Elanco’s second canine dermatology approval in under 18 months, reinforcing its push into higher‑value pet allergy treatments alongside Zenrelia and research on America’s “itchy dogs.” We’ll now examine how the Befrena approval, with its extended 6 to 8...

In February 2026, Caesars Entertainment announced it had released its fourth-quarter and full-year 2025 results and hosted a webcasted conference call, while investors also focused on reports that landlord VICI Properties might reduce the rent Caesars pays on its casino properties. This combination of fresh financial disclosure and uncertainty over a potential rent reset has sharpened attention on Caesars’ already significant debt load and the resilience of its cash flows. We’ll now examine...

In December 2025, Ramaco Resources, Inc. announced that KeyBank, N.A. amended its Revolving Credit Agreement, lifting total commitments to US$500 million, including a US$350 million revolver, a US$150 million accordion feature, and extending the facility’s maturity from 2029 to 2030. This sizable expansion of committed bank financing, alongside nearly US$1 billion of capital markets and banking transactions since August, underscores increased lender support and greater balance sheet...

In recent months, Best Buy highlighted its disciplined holiday promotional approach and emphasis on higher-margin services and memberships, aiming to protect profitability despite a challenging retail backdrop. This renewed focus on service-based offerings and margin resilience has drawn attention to how Best Buy may balance sales growth with earnings quality over time. We’ll now examine how Best Buy’s push into higher-margin services and memberships could influence its existing investment...